|
1
|
Estey E and Döhner H: Acute myeloid
leukemia. Lancet. 368:1894–1907. 2006. View Article : Google Scholar
|
|
2
|
Rubnitz JE, Gibson B and Smith FO: Acute
myeloid leukemia. Hematol Oncol Clin North Am. 24:35–63. 2010.
View Article : Google Scholar
|
|
3
|
Harrison CJ, Hills RK, Moorman AV, et al:
Cytogenetics of childhood acute myeloid leukemia: United Kingdom
Medical Research Council Treatment trials AML 10 and 12. J Clin
Oncol. 28:2674–2681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grimwade D: The clinical significance of
cytogenetic abnormalities in acute myeloid leukaemia. Best Pract
Res Clin Haematol. 14:497–529. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Döhner H, Estey EH, Amadori S, et al:
Diagnosis and management of acute myeloid leukemia in adults:
recommendations from an international expert panel, on behalf of
the European LeukemiaNet. Blood. 115:453–474. 2010.PubMed/NCBI
|
|
6
|
Naoe T, Suzuki T, Kiyoi H and Urano T:
Nucleophosmin: a versatile molecule associated with hematological
malignancies. Cancer Sci. 97:963–969. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Borer RA, Lehner CF, Eppenberger HM and
Nigg EA: Major nucleolar proteins shuttle between nucleus and
cytoplasm. Cell. 56:379–390. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan WY, Liu QR, Borjigin J, et al:
Characterization of the cDNA encoding human nucleophosmin and
studies of its role in normal and abnormal growth. Biochemistry.
28:1033–1039. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Colombo E, Marine JC, Danovi D, Falini B
and Pelicci PG: Nucleophosmin regulates the stability and
transcriptional activity of p53. Nat Cell Biol. 4:529–533. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Okuda M, Horn HF, Tarapore P, et al:
Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome
duplication. Cell. 103:127–140. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lindstrom MS: NPM1/B23: A multifunctional
chaperone in ribosome biogenesis and chromatin remodeling. Biochem
Res Int. 2011:1952092011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Falini B, Mecucci C, Tiacci E, et al:
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a
normal karyotype. N Engl J Med. 352:254–266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Verhaak RG, Goudswaard CS, van Putten W,
et al: Mutations in nucleophosmin (NPM1) in acute myeloid leukemia
(AML): association with other gene abnormalities and previously
established gene expression signatures and their favorable
prognostic significance. Blood. 106:3747–3754. 2005. View Article : Google Scholar
|
|
14
|
Thiede C, Koch S, Creutzig E, et al:
Prevalence and prognostic impact of NPM1 mutations in 1485 adult
patients with acute myeloid leukemia (AML). Blood. 107:4011–4020.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Döhner K, Schlenk RF, Habdank M, et al:
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger
adults with acute myeloid leukemia and normal cytogenetics:
interaction with other gene mutations. Blood. 106:3740–3746.
2005.PubMed/NCBI
|
|
16
|
Schnittger S, Schoch C, Kern W, et al:
Nucleophosmin gene mutations are predictors of favorable prognosis
in acute myelogenous leukemia with a normal karyotype. Blood.
106:3733–3739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Konoplev S, Huang X, Drabkin HA, et al:
Cytoplasmic localization of nucleophosmin in bone marrow blasts of
acute myeloid leukemia patients is not completely concordant with
NPM1 mutation and is not predictive of prognosis. Cancer.
115:4737–4744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mullighan CG, Kennedy A, Zhou X, et al:
Pediatric acute myeloid leukemia with NPM1 mutations is
characterized by a gene expression profile with dysregulated HOX
gene expression distinct from MLL-rearranged leukemias. Leukemia.
21:2000–2009. 2007. View Article : Google Scholar
|
|
19
|
Suzuki T, Kiyoi H, Ozeki K, et al:
Clinical characteristics and prognostic implications of NPM1
mutations in acute myeloid leukemia. Blood. 106:2854–2861. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gale RE, Green C, Allen C, et al: The
impact of FLT3 internal tandem duplication mutant level, number,
size, and interaction with NPM1 mutations in a large cohort of
young adult patients with acute myeloid leukemia. Blood.
111:2776–2784. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Becker H, Marcucci G, Maharry K, et al:
Favorable prognostic impact of NPM1 mutations in older patients
with cytogenetically normal de novo acute myeloid leukemia and
associated gene- and microRNA-expression signatures: a Cancer and
Leukemia Group B study. J Clin Oncol. 28:596–604. 2010. View Article : Google Scholar
|
|
22
|
Boonthimat C, Thongnoppakhun W and
Auewarakul CU: Nucleophosmin mutation in Southeast Asian acute
myeloid leukemia: eight novel variants, FLT3 coexistence and
prognostic impact of NPM1/FLT3 mutations. Haematologica.
93:1565–1569. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schnittger S, Haferlach C, Ulke M,
Alpermann T, Kern W and Haferlach T: IDH1 mutations are detected in
6.6% of 1414 AML patients and are associated with intermediate risk
karyotype and unfavorable prognosis in adults younger than 60 years
and unmutated NPM1 status. Blood. 116:5486–5496. 2010.
|
|
24
|
Yan L, Chen S, Liang J, et al: Analysis of
NPM1 gene mutations in Chinese adults with acute myeloid leukemia.
Int J Hematol. 86:143–146. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haferlach C, Mecucci C, Schnittger S, et
al: AML with mutated NPM1 carrying a normal or aberrant karyotype
show overlapping biologic, pathologic, immunophenotypic, and
prognostic features. Blood. 114:3024–3032. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen W, Rassidakis GZ, Li J, et al: High
frequency of NPM1 gene mutations in acute myeloid leukemia with
prominent nuclear invaginations (‘cuplike’ nuclei). Blood.
108:1783–1784. 2006.PubMed/NCBI
|
|
27
|
Paschka P, Schlenk RF, Gaidzik VI, et al:
IDH1 and IDH2 mutations are frequent genetic alterations in acute
myeloid leukemia and confer adverse prognosis in cytogenetically
normal acute myeloid leukemia with NPM1 mutation without FLT3
internal tandem duplication. J Clin Oncol. 28:3636–3643. 2010.
View Article : Google Scholar
|
|
28
|
Koh Y, Park J, Bae EK, et al: Non-A type
nucleophosmin 1 gene mutation predicts poor clinical outcome in de
novo adult acute myeloid leukemia: differential clinical importance
of NPM1 mutation according to subtype. Int J Hematol. 90:1–5. 2009.
View Article : Google Scholar
|
|
29
|
Palmisano M, Grafone T, Ottaviani E,
Testoni N, Baccarani M and Martinelli G: NPM1 mutations are more
stable than FLT3 mutations during the course of disease in patients
with acute myeloid leukemia. Haematologica. 92:1268–1269. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Zhang M, Yang L and Xiao Z: NPM1
mutations in myelodysplastic syndromes and acute myeloid leukemia
with normal karyotype. Leuk Res. 31:109–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wertheim G and Bagg A: Nucleophosmin
(NPM1) mutations in acute myeloid leukemia: an ongoing
(cytoplasmic) tale of dueling mutations and duality of molecular
genetic testing methodologies. J Mol Diagn. 10:198–202. 2008.
View Article : Google Scholar
|
|
32
|
Green CL, Koo KK, Hills RK, Burnett AK,
Linch DC and Gale RE: Prognostic significance of CEBPA mutations in
a large cohort of younger adult patients with acute myeloid
leukemia: impact of double CEBPA mutations and the interaction with
FLT3 and NPM1 mutations. J Clin Oncol. 28:2739–2747. 2010.
View Article : Google Scholar
|
|
33
|
Noguera NI, Ammatuna E, Zangrilli D, et
al: Simultaneous detection of NPM1 and FLT3-ITD mutations by
capillary electrophoresis in acute myeloid leukemia. Leukemia.
19:1479–1482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burnett AK, Hills RK, Green C, et al: The
impact on outcome of the addition of all-trans retinoic acid to
intensive chemotherapy in younger patients with nonacute
promyelocytic acute myeloid leukemia: overall results and results
in genotypic subgroups defined by mutations in NPM1, FLT3, and
CEBPA. Blood. 115:948–956. 2010.
|
|
35
|
Falini B: Therapy-related acute myeloid
leukaemia with mutated NPM1: treatment induced or de novo in
origin? Leukemia. 22:891–892. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Guyatt GH, Oxman AD, Vist GE, et al:
GRADE: an emerging consensus on rating quality of evidence and
strength of recommendations. BMJ. 336:924–926. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Meta-analysis of randomized clinical
trials comparing Cisplatin to Carboplatin in patients with advanced
non-small-cell lung cancer. J Clin Oncol. 22:3852–3859. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Begg CB and Mazumdar M: Operating
characteristics of a rank correlation test for publication bias.
Biometrics. 50:1088–1101. 1994. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Egger M, Davey SG, Schneider M and Minder
C: Bias in meta-analysis detected by a simple, graphical test. BMJ.
315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
DerSimonian R and Laird N: Meta-analysis
in clinical trials. Control Clin Trials. 7:177–188. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yanada M, Matsuo K, Suzuki T, Kiyoi H and
Naoe T: Prognostic significance of FLT3 internal tandem duplication
and tyrosine kinase domain mutations for acute myeloid leukemia: a
meta-analysis. Leukemia. 19:1345–1349. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Small D: FLT3 mutations: biology and
treatment. Hematol Am Soc Hematol Educ Program. 178–184. 2006.
View Article : Google Scholar
|
|
44
|
Kottaridis PD, Gale RE and Linch DC: Flt3
mutations and leukaemia. Br J Haematol. 122:523–538. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Feng JH, Guo XP, Chen YY, Wang ZJ, Cheng
YP and Tang YM: Prognostic significance of IDH1 mutations in acute
myeloid leukemia: a meta-analysis. Am J Blood Res. 2:254–264.
2012.PubMed/NCBI
|
